Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 14/20 | 0.41 |
| ▸ | CA2 | P00918 | 14/20 | 0.41 |
| ▸ | CA4 | P22748 | 8/20 | 0.41 |
| ▸ | CA5A | P35218 | 8/20 | 0.41 |
| ▸ | CA5B | Q9Y2D0 | 8/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10984129 | 0.70 | — | — | |
| SCHEMBL1850477 | 0.66 | — | — | |
| SCHEMBL15421709 | 0.66 | HCRTR1 (0.52) | ALDH1A1CA1CA2KMT2AMAPT | |
| SCHEMBL1007930 | 0.65 | — | — | |
| SCHEMBL11168362 | 0.64 | — | — | |
| SCHEMBL27698007 | 0.62 | CA1 (0.37) | CA1CA2CA4CA5ACA5B | |
| SCHEMBL1148587 | 0.62 | CA1 (0.37) | CA1CA2CA4CA5ACA5B | |
| SCHEMBL11497234 | 0.62 | — | — | |
| SCHEMBL10757451 | 0.62 | — | — | |
| SCHEMBL3508035 | 0.61 | MAPT (0.34) | ALDH1A1ATML3MBTL1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2594265-B1 | Ca ix-specific inhibitors | INST VIROLOGY (SK) | 2015-10-28 | — | — | EP | disclosed |
| US-8628771-B2 | CA IX-specific inhibitors | INSTITUTE OF VIROLOGY SLOVAK ACADEMY OF SCIENCES (SK) | 2014-01-14 | — | — | US | disclosed |
| EP-2594265-A1 | Ca ix-specific inhibitors | INSTITUTE OF VIROLOGY (SK) | 2013-05-22 | — | — | EP | disclosed |
| US-8025865-B2 | Carbonic anhydrase (CA); enhance the efficacy of weak base chemotherapeutic drugs; positively charged sulfonamides that have membrane impermeability | INSTITUTE OF VIROLOGY OF THE SLOVAK ACADEMY OF SCIENCES (SK) | 2011-09-27 | — | — | US | disclosed |
| US-7833734-B2 | CA IX-specific inhibitors | INSTITUTE OF VIROLOGY OF THE SLOVAK ACADEMY OF SCIENCES (SK) | 2010-11-16 | — | — | US | disclosed |
| US-7833514-B2 | CA IX-specific inhibitors | INSTITUTE OF VIROLOGY OF THE SLOVAK ACADEMY OF SCIENCES (SK) | 2010-11-16 | — | — | US | disclosed |
| US-7833739-B2 | CA IX-specific inhibitors | INSTITUTE OF VIROLOGY OF THE SLOVAK ACADEMY OF SCIENCES (SK) | 2010-11-16 | — | — | US | disclosed |
| US-7833738-B2 | CA IX-specific inhibitors | INSTITUTE OF VIROLOGY OF THE SLOVAK ACADEMY OF SCIENCES (SI) | 2010-11-16 | — | — | US | disclosed |
| US-7833737-B2 | CA IX-specific inhibitors | INSTITUTE OF VIROLOGY OF THE SLOVAK ACADEMY OF SCIENCES (SK) | 2010-11-16 | — | — | US | disclosed |
| US-7829065-B2 | CA IX-specific inhibitors | INSTITUTE OF VIROLOGY OF THE SLOVAK ACADEMY OF SCIENCES (SK) | 2010-11-09 | — | — | US | disclosed |
| US-20080159955-A1 | CA IX-Specific Inhibitors | INSTITUTE OF VIROLOGY SLOVAK ACADEMY OF SCIENCES (SK) | 2008-07-03 | — | — | US | disclosed |
| US-20080145877-A1 | Inhibiting the growth of tumor cells overexpressing MN protein with enzyme inhibitors of carbonic anhydrase (CA 1X) (MN protein); pyridinium derivatives of aromatic heterocyclic sulfonamides; side-effect reduction; antitumor, -carcinogenic, -metastasis agents | INSTITUTE OF VIROLOGY SLOVAK ACADEMY OF SCIENCES (SK) | 2008-06-19 | — | — | US | disclosed |
| US-20080146618-A1 | Inhibiting the growth of tumor cells overexpressing MN protein with enzyme inhibitors of carbonic anhydrase (CA 1X) (MN protein); pyridinium derivatives of aromatic heterocyclic sulfonamides; side-effect reduction; antitumor, -carcinogenic, -metastasis agents | INSTITUTE OF VIROLOGY SLOVAK ACADEMY OF SCIENCES (SK) | 2008-06-19 | — | — | US | disclosed |
| US-20080145874-A1 | CA IX-Specific Inhibitors | INSTITUTE OF VIROLOGY SLOVAK ACADEMY OF SCIENCES (SK) | 2008-06-19 | — | — | US | disclosed |
| US-20080095707-A1 | CA IX-SPECIFIC INHIBITORS | INSTITUTE OF VIROLOGY SLOVAK ACADEMY OF SCIENCES (SK) | 2008-04-24 | — | — | US | disclosed |
| EP-1569633-A4 | CA IX-SPECIFIC INHIBITORS | INST VIROLOGY (SK) | 2008-03-05 | — | — | EP | disclosed |
| US-20060057068-A1 | CA IX-specific inhibitors | INSTITUTE OF VIROLOGY SLOVAK ACADEMY OF SCIENCES (SK) | 2006-03-16 | — | — | US | disclosed |
| EP-1569633-A2 | CA IX-SPECIFIC INHIBITORS | INSTITUTE OF VIROLOGY (SK) | 2005-09-07 | — | — | EP | disclosed |
| US-20040146955-A1 | CA IX-specific inhibitors | INSTITUTE OF VIROLOGY SLOVAK ACADEMY OF SCIENCES (SK) | 2004-07-29 | — | — | US | disclosed |
| WO-2004048544-A2 | CA IX-SPECIFIC INHIBITORS | BAYER HEALTHCARE (US) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080159955-A1 | CA IX-Specific Inhibitors | CA9, CA2, CA6 | ALDH1A1 2367/4885ATM 3534/4885L3MBTL1 2657/4885 |
| US-20080095707-A1 | CA IX-SPECIFIC INHIBITORS | CA9, CA6, CA14 | ALDH1A1 2537/4885ATM 3305/4885L3MBTL1 3950/4885 |
| US-20060057068-A1 | CA IX-specific inhibitors | CA9, CA2, CA6 | ALDH1A1 2367/4885ATM 3534/4885L3MBTL1 2657/4885 |
| US-20080146618-A1 | Inhibiting the growth of tumor cells overexpressing MN protein with enzyme inhibitors of carbonic anhydrase (CA 1X) (MN protein); pyridinium derivatives of aromatic heterocyclic sulfonamides; side-effect reduction; antitumor, -carcinogenic, -metastasis agents | CA2, CA9, CA1 | ALDH1A1 1473/4885ATM 3310/4885L3MBTL1 1971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.